8-K: Lyell Immunopharma Unveils Promising LYL314 CAR T-Cell Data for Large B-Cell Lymphoma

Lyell Immunopharma, Inc. announced new positive clinical data from its Phase 1/2 trial of LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate, showing high response rates and a manageable safety profile in patients with large B-cell lymphoma.

Summary

• Lyell Immunopharma, Inc. announced new clinical data for LYL314, an autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate.
• LYL314 is designed to improve complete response rates and duration compared to approved CD19-targeted CAR T-cell therapies for Large B-cell Lymphoma (LBCL).
• The PiNACLE single-arm pivotal trial of LYL314 (100 x 10^6 CAR T cells) is underway in 3L+ LBCL patients, targeting approximately 120 relapsed and/or refractory (R/R) patients who have not previously received CAR T-cell therapy.
• As of April 15, 2025 (data cutoff), 51 CAR T-naive R/R LBCL patients received LYL314.
• In efficacy-evaluable 3L+ patients (N=25, median follow-up 9 months): The overall response rate (ORR) was 88% (22/25), with 72% (18/25) achieving a complete response (CR). 71% (10/14) of CR patients remained in CR at 6 months.
• In initial efficacy-evaluable 2L patients (N=11, median follow-up 5 months): The ORR was 91% (10/11), with 64% (7/11) achieving CR. 100% (7/7) of CR patients were in CR at last assessment, including 3/3 at 6 months.
• In patients with primary refractory disease (N=10), 70% (7/10) achieved CR, despite having high-risk features.
• A manageable safety profile appropriate for outpatient administration was observed across 51 patients.
• No Grade >=3 cytokine release syndrome (CRS) was reported, with low rates of Grade 1 (22%) and Grade 2 (35%) CRS.
• Immune effector cell-associated neurotoxicity syndrome (ICANS) was reported in 6% (Grade 1), 2% (Grade 2), and 14% (Grade >=3) of patients. The median time to complete resolution of all ICANS reports was 5 days.
• No deaths were related to LYL314 administration.
• LYL314 demonstrated robust expansion with a time to peak of 10 days and rapid/durable B-cell depletion through month 6 and up to month 12.
• The Company expects to initiate a randomized pivotal trial of LYL314 in patients with R/R LBCL in the 2L setting by early 2026.
• The Company's LyFE Manufacturing Center is expected to manufacture over 1,200 CAR T-cell therapy doses at full capacity, supporting clinical development and early commercial launch if approved.

Sentiment

Score: 8

Explanation: The clinical data presented for LYL314 is highly positive, showing strong efficacy in difficult-to-treat patient populations and a manageable safety profile. The planned progression to a randomized pivotal trial and manufacturing capacity are also favorable. The only minor caveats are the inherent risks of clinical development and the high-risk nature of the patient population, but the drug's performance against these challenges is encouraging.

Positives

• High overall response rate of 88% and complete response rate of 72% in 3L+ LBCL patients, indicating strong efficacy in a heavily pre-treated population.
• Strong initial data in 2L LBCL patients with 91% ORR and 64% CR, suggesting potential for earlier line treatment.
• Significant complete response rate of 70% in difficult-to-treat primary refractory disease patients, addressing a high unmet medical need.
• Manageable safety profile observed, suitable for outpatient administration, which could enhance patient access and reduce healthcare burden.
• No Grade >=3 cytokine release syndrome (CRS) reported, with low rates of Grade 1 (22%) and Grade 2 (35%) CRS.
• Immune effector cell-associated neurotoxicity syndrome (ICANS) resolved rapidly (median 5 days for complete resolution, 2 days to Grade 2 or lower).
• No deaths were related to LYL314 administration, highlighting a favorable safety outcome.
• Robust expansion and durable B-cell depletion demonstrated, supporting the therapeutic mechanism.
• Company's LyFE Manufacturing Center has capacity to manufacture over 1,200 CAR T-cell therapy doses, supporting clinical needs and early commercial launch if approved.

Negatives

• The patient populations treated (3L+ and 2L) had high-risk characteristics, including older age, Stage IV disease, and primary refractory disease, which inherently presents challenges for treatment.
• 14% of patients experienced Grade >=3 ICANS, which, while resolving, is a notable adverse event that requires careful management.

Risks

• Potential for results from clinical trials to differ from nonclinical, early clinical, preliminary, or expected results.
• Significant adverse events, toxicities, or other undesirable side effects associated with the Company's product candidates.
• The Company's ability to initiate or progress clinical trials on the anticipated timelines, if at all.
• The Company's limited experience as a company in enrolling and conducting clinical trials and lack of experience in completing clinical trials.
• The complexity of manufacturing cellular therapies and the Company's ability to manufacture and supply its product candidates for its clinical trials.
• The significant uncertainty associated with the Company's product candidates ever receiving any regulatory approvals.
• The effects of macroeconomic conditions.
• Other risks, including general economic conditions and regulatory developments, not within the Company's control.
• Other risks described under the heading Risk Factors in Lyell's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 13, 2025.

Future Outlook

The Company expects to initiate a randomized pivotal trial of LYL314 in patients with relapsed and/or refractory large B-cell lymphoma in the second-line setting by early 2026. The LyFE Manufacturing Center is expected to support clinical development and early commercial launch of LYL314, if approved, with a capacity of over 1,200 CAR T-cell therapy doses at full staffing.

Industry Context

LYL314 is positioned as an autologous dual-targeting CD19/CD20 CAR T-cell product candidate, designed to improve upon existing approved CD19-targeted CAR T-cell therapies by increasing complete response rates and prolonging response duration. This dual-targeting approach aims to address limitations of single-target therapies and potentially offer a more effective option in the challenging large B-cell lymphoma landscape, particularly for relapsed and refractory patients.

Comparison to Industry Standards

• LYL314 is designed to increase complete response rates and prolong the duration of responses as compared to approved CD19-targeted CAR T-cell therapies for the treatment of LBCL.
• The observed overall response rate of 88% and complete response rate of 72% in 3L+ LBCL patients, and 91% ORR and 64% CR in 2L patients, including a 70% CR in primary refractory disease, appear highly competitive, especially given the high-risk patient populations.
• The manageable safety profile, including no Grade >=3 CRS and rapid resolution of ICANS, suggests a potentially favorable safety profile compared to some existing CAR T-cell therapies which can have more severe toxicity profiles.
• The ability to administer LYL314 in an outpatient setting, as suggested by the safety profile, could offer a significant logistical and cost advantage over therapies requiring inpatient administration.

Stakeholder Impact

• Shareholders: Positive impact due to promising clinical trial results, which could increase company valuation and future revenue potential if LYL314 receives regulatory approval.
• Patients: Potential for a new, effective, and potentially safer treatment option for large B-cell lymphoma, especially for those who have relapsed or are refractory to other therapies.
• Employees: Positive impact due to progress in the company's pipeline and potential for future commercialization, which could lead to job security and growth opportunities.

Next Steps

• Continue the PiNACLE single-arm pivotal trial of LYL314 in 3L+ LBCL patients.
• Initiate a randomized pivotal trial of LYL314 in patients with R/R LBCL in the 2L setting by early 2026.

Key Dates

Recommendation

Keywords

Lyell Immunopharma, LYL314, CAR T-cell therapy, Large B-cell Lymphoma, LBCL, CD19, CD20, oncology, hematology, clinical trial, Phase 1/2, PiNACLE, relapsed refractory, R/R, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, follicular lymphoma, cytokine release syndrome, CRS, ICANS, neurotoxicity, LyFE Manufacturing Center